<p>Base case cost-effectiveness results of inclisiran vs. statin alone in Chinese ASCVD pa

5.5 KB of cost-effectiveness results comparing inclisiran to statin therapy for Chinese patients with atherosclerotic cardiovascular disease. The data was authored by Mochou Liu and last updated on May 28, 2026. It is shared under a CC-BY-4.0 license on the figshare platform.

Use Cases

• Compare cost-effectiveness ratios between inclisiran and statin therapy based on the described base case analysis.
• Inform healthcare policy and reimbursement decisions for ASCVD treatments in China based on the pharmacoeconomic results.
• Validate or calibrate other economic models for lipid-lowering therapies using the provided base case data.

Strengths

• File size is precisely 5.5 KB, indicating a focused and specific dataset.
• License is explicitly stated as CC-BY-4.0, allowing for clear reuse.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.

Provenance

Source

Mochou Liu

Freshness

Last updated 2026-05-28 17:30:45; freshness should be verified.

Geography

China